On Wednesday, Shares of Union Pacific Corporation (NYSE:UNP), lost -0.71% to $103.28.
Union Pacific Railroad was honored with the “Club Elite” award by Hyundai GLOVIS, a logistics supplier for Hyundai Motor America and Kia Motors America. The recognition designates Union Pacific as a top service provider exhibiting dedication to superior transportation solutions for finished vehicles.
“Union Pacific is thrilled to receive this recognition from Hyundai GLOVIS again this year,” said Linda Brandl, Union Pacific’s vice president-Automotive. “Fostering an environment of continuous improvement and innovation, we are committed to providing our valued customers with exceptional logistics solutions and service.”
Union Pacific Corporation, through its partner, Union Pacific Railroad Company, operates railroads in the United States. The company offers freight transportation services for agricultural products, counting grains, commodities produced from grains, and food and beverage products; automotive products, such as finished vehicles and automotive parts; and chemicals comprising of industrial chemicals, plastics, crude oil, liquid petroleum gases, fertilizers, soda ash, sodium products, and phosphorus rock and sulfur products.
Shares of Fiat Chrysler Automobiles NV (NYSE:FCAU), inclined 0.96% to $15.75, during its last trading session.
The FCA Foundation declared a $100,000 grant to support scholarships for current and future African American farmers. The National Black Farmers Association Scholarship program will provide scholarships up to $5,000 to fund agriculture-related study at an accredited two-year or four-year college, university or vocational-technical school.
“We should accept nothing less than a world in which everyone has access to a safe, healthy and sufficient food supply,” said Jody Trapasso, Senior Vice President – External Affairs, FCA North America and President of the FCA Foundation. “Our hope is that these scholarships provide farmers with the inspiration and knowledge to assist this vision become a reality.”
Fiat Chrysler Automobiles N.V., an automotive group, designs, engineers, manufactures, distributes, and sells vehicles and components. It offers passenger cars, light trucks, and light commercial vehicles under the Abarth, Alfa Romeo, Chrysler, Dodge, Fiat, Fiat Professional, Jeep, Lancia, and Ram brand names, in addition to after-sales services and parts under the Mopar brand name.
At the end of Wednesday’s trade, Shares of AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) gained 19.40% to $1.60.
AVEO Oncology (AVEO) declared that final results from the TIVO-1 extension study, known as Study 902, in which patients with advanced renal cell carcinoma (RCC) received tivozanib as second-line treatment subsequent to disease progression on sorafenib in the Company’s Phase 3 TIVO-1 first-line RCC study, will be presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting. The Company formerly stated interim median progression free survival (PFS) results of 8.4 months among the 163 patients enrolled in Study 902. Final results now show a median PFS in this setting of 11.0 months and median overall survival (OS) of 21.6 months, demonstrating the efficacy of tivozanib in a VEGF treatment refractory population.
AVEO also declared that it has received a written response from the U.S. Food and Drug Administration (FDA) stating that a phase 3 study outlined by the Company, in patients with RCC who have failed at least two preceding regimens, counting VEGF therapy, “may support AVEO’s projected indication for tivozanib in the 3rd line setting.” In response to whether the study, together with the TIVO-1 study, would be sufficient to support licensure of tivozanib as a treatment for advanced RCC, the FDA indicated: “whether the results from this [third line] study can support AVEO’s proposal for tivozanib in the first line setting is a review issue.”
AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted therapies for patients with cancer and related diseases. Its product candidates under development comprise Tivozanib, an tyrosine kinase inhibitor for various vascular endothelial growth factors; Ficlatuzumab, a hepatocyte growth factor inhibitory antibody, which has accomplished Phase II trial; and AV-203, an anti-ErbB3 monoclonal antibody that has accomplished a Phase I dose escalation study.
Finally, Kearny Financial Corp. (NASDAQ:KRNY), ended its last trade with 0.75% gain, and closed at $10.80.
Kearny Financial Corp., declared that it has accomplished its stock offering and the related conversion from the mutual holding company to the stock holding company form of organization. As a result of the closing of the conversion and stock offering, the Company is now the holding company for Kearny Bank. Kearny Financial Corp. and Kearny MHC, the Bank’s former mutual holding company, have ceased to exist. The results of the stock offering were formerly stated in Kearny-Federal’s press release dated May 14, 2015.
Kearny Financial Corp. operates as a holding company for Kearny Federal Savings Bank that provides various banking products and services. The company offers various deposit products, counting interest-bearing and non-interest-bearing checking accounts, money market deposit accounts, savings accounts, and certificates of deposit accounts.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
